Search results
Results from the WOW.Com Content Network
Distribution of Alberta's 19 cities and 12 other communities eligible for city status. To qualify as a city in Alberta, a sufficient population size (10,000 people or more) must be present and a majority of the buildings must be on parcels of land less than 1,850 square metres (19,900 sq ft). [1]
The table below lists the 100 largest census subdivisions (municipalities or municipal equivalents) in Canada by population, using data from the 2021 Canadian census for census subdivisions. [1] This list includes only the population within a census subdivision's boundaries as defined at the time of the census.
While Canada's ten provinces and three territories exhibit high per capita GDPs, there is wide variation among them. Ontario , the country's most populous province, is a major manufacturing and trade hub with extensive linkages to the northeastern and midwestern United States .
This is a list of the census metropolitan areas and agglomerations in Canada by population, using data from the 2021 Canadian census and the 2016 Canadian census. [1] Each entry is identified as a census metropolitan area (CMA) or a census agglomeration (CA) as defined by Statistics Canada.
Canada population density map (2014). A population centre, in the context of a Canadian census, is a populated place, or a cluster of interrelated populated places, which meets the demographic characteristics of an urban area, having a population of at least 1,000 people and a population density of no fewer than 400 people per square km 2.
Volume growth of Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature ...
These definitions vary from country to country. For example, for U.S. cities, the list uses Metropolitan Statistical Areas as defined by the United States Census Bureau, and for Canadian cities the list uses Census Metropolitan Areas as defined by Statistics Canada.
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.